matt7810 t1_j3h1uf7 wrote on January 8, 2023 at 2:59 PM

Reply to comment by jaiagreen in A randomized double-blind controlled trial found post-exposure prophylaxis with hydroxychloroquine (HCQ) was not advantageous for the prevention of COVID-19 in asymptomatic individuals with high risk for SARS-CoV-2 infection. The incidence of COVID-19 was similar in both the HCQ group and control. by glawgii

Because if covid is going to be around for a long time, it would be incredibly helpful to have a generic drug help avoid deaths. HCQ is a promising candidate (as stated in the article) and not every country has 5.3 billion dollars to get free paxlovid for their population.

Unfortunately, they don't seem to work but devoting a relatively small amount of funding to check seems fair to me.

jaiagreen t1_j3ibake wrote on January 8, 2023 at 7:52 PM

Yes, it would, and there already are some, but at this point there are so many negative results that this seems like a waste of resources. A randomly chosen drug would be more promising -- at least it wouldn't have a bunch of evidence against it.